Vivos Therapeutics Q2 2024 GAAP EPS $(0.60) Beats $(0.92) Estimate, Sales $4.05M Beat $3.60M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics (NASDAQ:VVOS) reported Q2 2024 GAAP EPS of $(0.60), beating the $(0.92) estimate by 34.78%. Sales were $4.05M, surpassing the $3.60M estimate by 12.61% and marking a 19.41% increase from the same period last year.
August 14, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vivos Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.60) beating estimates by 34.78% and sales of $4.05M beating estimates by 12.61%. Sales also increased by 19.41% year-over-year.
The better-than-expected earnings and sales figures are likely to positively impact VVOS's stock price in the short term. Beating both EPS and sales estimates by significant margins and showing year-over-year growth are strong indicators of the company's improving financial health.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100